장기 호스트 병원체 상호 작용을 특성화에 대한 EpiAirway 모델의 사용

Executive Industry Relevance

The EpiAirway model enables long-term co-culture of respiratory pathogens with primary human epithelial tissues, addressing a critical gap in preclinical infection modeling. This approach supports mechanistic de-risking of host-pathogen interactions and improves predictive confidence in early-stage antimicrobial target validation. By maintaining tissue integrity and physiological relevance over extended periods, it enhances translational continuity from discovery to preclinical development.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses through quantification of cell-associated and internalized bacteria over time.
• Operational Value: Supports functional target validation by assessing strain-specific survival characteristics in a human-relevant system.
• Scientific Value: Facilitates biological de-risking by modeling chronic infection phenotypes not supported by submerged cultures.

Screening & Assay Development

• Scientific Value: Provides quantitative dependent variable measurements (CFU counts) for evaluating antimicrobial efficacy and bacterial persistence.
• Operational Value: Enables assay standardization through daily washing with pre-warmed DPBS to mimic mucociliary clearance and reduce variability.
• Scientific Value: Supports screening readiness by allowing mucin production and cytokine profiling as secondary readouts for host response.

Translational & Preclinical Research

• Scientific Value: Uses disease-relevant system (normal human tracheo-bronchial cells) to improve translational biomarker alignment for respiratory infections.
• Operational Value: Ensures continuity from discovery through preclinical work by maintaining tissue structure and function during long-term co-culture.
• Scientific Value: Enables risk-adjusted advancement decisions by characterizing long-term host-pathogen interactions without significant apical tissue damage.

Pipeline & Workflow Integration

The method fits within the discovery continuum from early target validation to preclinical efficacy testing, particularly for respiratory antimicrobial development.

• Discovery Biology: Supports hypothesis testing and pathway clarification by enabling longitudinal tracking of bacterial adherence, invasion, and survival.
• Screening: Delivers assay readiness and reproducibility via standardized inoculum preparation (OD 600 nm ~0.7) and serial dilution plating for viable bacterial counts.
• Analytics: Generates quantitative readouts (CFU/mL) that allow comparison of strain-specific survival and evaluation of intervention effects.
• Translational Research: Connects to preclinical continuity through use of primary human tissues that retain cytokine production and mucin secretion capabilities.
• Enterprise Reuse: Represents a reusable platform adaptable to other respiratory pathogens (e.g., Moraxella catarrhalis) beyond NTHi.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in target validation through reduction of mechanistic ambiguity in chronic infection models.
• Operational Value: Standardization and reproducibility via antibiotic-free conditions and defined washing protocols.
• Strategic Value: Better go/no-go decisions by identifying compounds that reduce bacterial internalization or persistence over time.
• Portfolio Impact: Risk-adjusted prioritization based on longitudinal infection dynamics rather than acute cytotoxicity endpoints.

Implementation Considerations

• Requires expertise in primary tissue handling and biosafety level 2 practices for co-culture of bacteria and human cells.
• Dependent on specialized inserts and air-liquid interface culture systems (e.g., MatTek EpiAirway).
• Necessitates cross-team standardization of inoculum preparation, washing frequency, and harvesting procedures.
• Adaptation considerations include validation of pathogen compatibility with mucociliary clearance mimicry and tissue integrity over time.
• Practical limitation: Extended co-culture increases contamination risk, requiring strict aseptic technique in shared biosafety cabinets.

Biopharma FAQs